DarioHealth Corp. (NASDAQ:DRIO) is set to announce third quarter earning results on Thursday 12th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, DRIO to report 3Q20 loss of $ 0.68 per share.
For the full year, analysts anticipate top line of $ 7.70 million, while looking forward to loss of $ 4.41 per share bottom line.
Previous Quarter Performance
DarioHealth Corp. outlined loss for the second quarter of $ 0.68 per share, from the revenue of $ 1.79 million. The quarterly revenues declined 26.94 percent compared with the same quarter last year. Street analysts expected DarioHealth Corp. to report loss of $ 1.40 per share on revenue of $ 1.55 million for the second quarter. The bottom line results beat street analysts by $ 0.72 or 51.43 percent, at the same time, top line results outshined analysts by $ 0.24 million or 15.48 percent.
Stock Performance
Shares of DarioHealth Corp. traded up $ 0.09 or 0.83 percent on Wednesday, reaching $ 10.92 with volume of 85.30 thousand shares. DarioHealth Corp. has traded high as $ 11.15 and has cracked $ 10.72 on the downward trend
The closing price of $ 10.92, representing a 5,315.00 % increase from the 52 week low of $ 0.20 and a 51.85 % decrease over the 52 week high of $ 22.49.
The company has a market capital of $ 82.89 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
DarioHealth Corp. will be hosting a conference call at 9:00 AM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 844-369-8770 U.S. or 862-298-0840 Outside U.S. in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.mydario.com
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The companys flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It offers Dario Engage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis.
